Supporting Health Including Endocrine Treatment for Long Duration
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Clinical Trials Related to ER Positive Breast Cancer
Related studies linked through entity extraction aliases.
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Status
- RECRUITING
- Phase
- PHASE2
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Status
- RECRUITING
- Phase
- PHASE1
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Status
- RECRUITING
- Phase
- PHASE2
Role of the Immune Environment in Response to Therapy in Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant + Neratinib In Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- Status
- RECRUITING
- Phase
- PHASE2
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
D4 Choline Breast PET/CT
- Status
- COMPLETED
- Phase
- N/A
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2